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Objective. An outbreak of 20 peripartum Clostridium diﬃcile infections (CDI) occurred on the obstetrical service at the University
of Washington Medical Center (UWMC) between April 2006 and June 2007. In this report, we characterize the clinical
manifestations, describe interventions that appeared to reduce CDI, and determine potential risk factors for peripartum CDI.
Methods.AninvestigationwasinitiatedaftertheﬁrstthreeperipartumCDIcases.Basedontheﬁndings,enhancedinfectioncontrol
measures and a modiﬁed antibiotic regimen were implemented. We conducted a case-control study of peripartum cases and
unmatched controls. Results. During the outbreak, there was an overall incidence of 7.5 CDI cases per 1000 deliveries. Peripartum
CDI infection compared to controls was signiﬁcantly associated with cesarean delivery (70% versus 34%; P = 0.03 ), antibiotic
use (95% versus 56%; P = 0.001), chorioamnionitis (35% versus 5%; P = 0.001), and the use of the combination of ampicillin,
gentamicin, and clindamycin (50% versus 3%; P<0.001 ). Use of combination antibiotics remained a signiﬁcant independent risk
factor for CDI in the multivariate analysis. Conclusions. The outbreak was reduced after the implementation of multiple infection
control measures and modiﬁcation of antibiotic use. However, sporadic CDI continued for 8 months after these measures slowed
the outbreak. Peripartum women appear to be another population susceptible to CDI.
1.Introduction
The patient populations susceptible to Clostridium diﬃcile
infection (CDI) have now broadened to include pregnant
women.Innonpregnantpopulations,boththeincidenceand
severity of CDI have increased over the past decade. Recent
large CDI outbreaks in Canada and U.S.A. demonstrated an
increase CDI infection rate from a baseline of 2–6 infections
per 1,000 hospitalized discharges (HD) in the 1990’s [1–3]
to 10–20 infections per 1,000 HD during recent outbreaks
[4, 5]. As with nonpregnant patients, the incidence of CDI
also has increased signiﬁcantly in peripartum women. Using
the Nationwide Inpatient Sample of all payer U.S. hospital
discharges, the number of nationally reported peripartum
CDI cases doubled from 129 cases in 1998 to 294 cases
in 2006; the estimated CDI incidence among peripartum
women increased signiﬁcantly from about 0.4 to 0.7 per
100,000 deliveries over this period [6]. While the apparent
lower rate of CDI in peripartum than nonpregnant patients
explains the sporadic reporting of peripartum CDI [7–10],
severe manifestations including septic shock, toxic mega
colon, and even death occur in the peripartum population
[8–10].
Antibiotics signiﬁcantly decrease both maternal and
neonatal infections, but they also are the primary risk factor
for CDI, the leading cause of nosocomial infectious diarrhea
[11]. Antibiotics disrupt normal bowel ﬂora and promote
colonic C. diﬃcile overgrowth and subsequent exotoxin
production. Prolonged antibiotic and multiple antibiotic
uses are particularly associated with CDI [12]. Exposure to2 Infectious Diseases in Obstetrics and Gynecology
C. diﬃcile spores occurs from direct transmission among
hospitalizedpatientsorindirectlythroughfomitesandhealt-
hcare workers [1, 13]. Thus, CDI risk factors in nonpregnant
populations also include prolonged hospitalization as well as
underlying disease, ICU care and elderly age [2].Up to 50%
of pregnant women now are exposed to antibiotics during
a hospital delivery; prophylactic antibiotics are used for the
30% of women undergoing cesarean section in the U.S [14]
and for the 15–20% of women with vaginal Group B strepto-
coccuscolonizationtopreventneonatalinfection[15].Addi-
tionally, about 10% of women develop chorioamnionitis
or postpartum endometritis infection requiring antibiotics
[16]. Although single extended spectrum antibiotics pro-
vide comparable infection cure rates to multiple antibiotic
regimens for postpartum endometritis [17], gentamicin and
clindamycin with or without the addition of ampicillin
continue to be a popular regimen to treat peripartum
infection [18].
The University of Washington Medical Center (UWMC)
is a 450 bed tertiary care teaching hospital with a high-
risk referral obstetrical service and 2200 annual deliveries.
In April 2006, the ﬁrst case of peripartum CDI in two years
was identiﬁed; over the following ﬁfteen months, a total of
twenty peripartum CDI cases were documented. Only two
peripartum CDI cases were identiﬁed at UWMC in the prior
ﬁve years. In this report, we sought to (1) characterize the
clinical manifestations and outcomes of the ﬁrst reported
sustained peripartum CDI outbreak, (2) outline speciﬁc
infection control measures and antibiotic modiﬁcations that
may have limited the outbreak, and (3) determine potential
risk factors of peripartum CDI through a case-control study.
2.MaterialsandMethods
Peripartum was deﬁned as four weeks before and four
weeks after delivery. A case of peripartum CDI was deﬁned
by diarrhea and evidence of CDI documented by either a
positive assay for C. diﬃcile A or B toxin in the stool or
colonic histopathology characteristic of C. diﬃcile infection
in a peripartum female. The presence of toxigenic C. diﬃcile
was identiﬁed in fecal specimens assayed simultaneously
for C. diﬃcile common antigen and toxin A by enzyme
immunoassay (Triage C. diﬃcile Panel). Specimens that were
antigen positive, but toxin A negative were cultured for C.
diﬃcile,followedbyPCRmoleculartestingforC.diﬃcile16S
gene and toxin B gene (an internally validated UW assay). In
addition, at the discretion of the primary care provider, fecal
specimens were assayed for cytotoxin B demonstrated by
cytotoxic eﬀects on human diploid ﬁbroblast cells that were
neutralized by C. diﬃcile antitoxin (an internally validated
UW assay) [19]. Several cases had more than one stool
sample submitted for diagnostic testing. In such cases, the
data was veriﬁed to represent the test date that corresponded
to the diagnosis of CDI, and results were consolidated in the
result section and in Table 1.
2.1.“Bundle”Interventions. AftertheﬁrstthreecasesofCDI,
the UWMC Infection Control Department started an inves-
tigation and infection control audit July 2006 (Figure 1).
0
1
2
3
4
5
6
“
2
0
0
5
”
M
a
r
-
0
6
A
p
r
-
0
6
M
a
y
-
0
6
J
u
n
-
0
6
J
u
l
-
0
6
A
u
g
-
0
6
S
e
p
-
0
6
O
c
t
-
0
6
N
o
v
-
0
6
D
e
c
-
0
6
J
a
n
-
0
7
F
e
b
-
0
7
M
a
r
-
0
7
A
p
r
-
0
7
M
a
y
-
0
7
J
u
n
-
0
7
“
2
0
0
8
”
C
D
I
c
a
s
e
s
Infection
control
investigation
Initiation of
antibiotic
changes
Environmental
cleaning
Initiation of
staﬀ
training
Figure 1: Clostridium diﬃcile infection outbreak timeline and
interventions.
By August 2006, step-wise comprehensive infection control
measures similar to the previously described “bundle”
approach [5] were initiated on the obstetrical unit (Table 3).
PatientswithconﬁrmedCDIwereplacedinstrictcontact
isolation that consisted of single room occupancy and gown
and glove used by all visitors and personnel. All patients with
diarrhea were placed on contact precautions until a negative
toxin result was available. Patients with conﬁrmed CDI were
initially treated with a ten-day course of oral metronidazole.
Immediately following the ﬁrst cases, all providers and
staﬀ underwent intensive formal education and training on
CDI prevention strategies (Table 3). All health care providers
were required to use contact precautions and soap and
water hand washing before and after any contact with C.
diﬃcile positive patients. Contact precautions included the
use of gowns and gloves with any contact with a presumed
or conﬁrmed CDI case. Further, a water-based scrub was
required for the ﬁrst surgical case of the day instead of the
previously used alcohol-based scrub. A thorough cleaning
of the antepartum, labor and delivery, postpartum and
outpatient clinic areas took place in September 2006. All
patient environment and equipment was disinfected using
a chlorine-based product (Bru-Clean TbC) rather than the
routine hospital quaternary ammonium disinfectants as
currently recommended [12]. A provider change room was
installed by the operating room on labor and delivery to
make clean scrubs readily accessible to providers after all
deliveries. Carpet in the provider workrooms was replaced
with hard wood laminated ﬂoors. Steps were made for the
immediate diagnoses of CDI among patients with diarrhea.
Finally, a multidisciplinary team of providers and infec-
tion control specialists reviewed the most common microor-
ganisms causing peripartum infection [20] and institutional
susceptibility data to commonly used antibiotics. Antibiotic
treatment was standardized for chorioamnionitis and post-
partum endometritis to reduce the utilization of multiple
antibiotics with a reported high resistance to C. diﬃcile.A sa
result, ticarcillin/clavulanate (Timentin) was routinely used
to treat chorioamnionitis and postpartum endometritis.
Clindamycin was restricted to severe or unusual infection.
Ampicillin and erythromycin use was continued for preterm
premature rupture of membranes (PPROMs).Infectious Diseases in Obstetrics and Gynecology 3
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The infection control “bundle” strategies were progres-
sively implemented until after the outbreak peaked. The
antibiotic transition strategies were gradually phased in and
became routine by early 2007. Infection control remains
heightened on the unit including soap and water washing,
frequent changing of scrubs, strict contact precautions, and
a narrow spectrum of antibiotic choices.
2.2. Case-Control Study. Peripartum CDI risk factors may
diﬀer from those reported in CDI of nonpregnant adults.
Thus, we performed a case-control study comparing peri-
partum CDI cases to randomly chosen unmatched controls
who delivered during the outbreak period of April 2006
to June 2007. Using a random number table, four controls
(n = 80) per case were selected from a hospital perinatal
databaseofdeliveriesduringthestudyperiod.Demographic,
clinical, laboratory and outcome data were abstracted from
medical records of both cases and controls. Data abstracted
included CDI risk factors such as age, underlying disease,
speciﬁc peripartum antimicrobial indication and use, length
of hospitalization, and mode of delivery. No patient was
excluded.
2.3. Statistical Methods. We performed chi-square (χ2)a n d
Fischer’s exact tests for univariate analysis of categorical
variables and Mann-Whitney U tests for continuous vari-
ables. All tests were 2 tailed, and a P<. 05 was considered
statistically signiﬁcant. We performed a logistic regression
using CDI as the outcome. The mode of delivery, antibiotic
use, and use of the antibiotic combination of clindamycin,
gentamicin, and ampicillin were included in the model.
Statistical analyses were performed with SPSS for Windows,
version 12.0 (SPSS). The study was approved by the UWMC
Human Subjects Committee no. 36114 under minimal risk
criteria.
3. Results
Twenty peripartum CDI cases were identiﬁed during the
ﬁfteen-month outbreak. A total of 2671 deliveries occurred
over this time for an incidence of 7.5 CDI cases per 1,000
deliveries. CDI was diagnosed by the presence of a positive
C. diﬃcile EIA assay for Toxin A alone in eight patients, by
the presence of a positive C. diﬃcile PCR and/or cytotoxin
assay for Toxin B alone in six patients, and by the presence of
positive assays for both Toxin A and B in six cases (Table 1).
Three cases developed CDI during a separate antepartum
admission, seven cases were diagnosed during their delivery
hospitalization, and ten postpartum cases were diagnosed
afterhospitaldischarge,eightofwhomrequiredreadmission.
Hospital readmission occurred back into the postpartum
ward.
No signiﬁcant clinical or antibiotic management change
occurred on the obstetrical ward prior to the outbreak. The
ﬁrst two cases of the outbreak were diagnosed during the
antepartum period. The ﬁrst patient received clindamycin
alone for preterm labor GBS prophylaxis at 32 weeks
gestation and developed diarrhea 7 days later. A positive
cytotoxin assay for C. diﬃcile Toxin B was identiﬁed in
her stool on hospital day 8. The patient delivered during a
second hospitalization at 36 weeks gestation (Table 1). The
second case presented with PPROM at 27 weeks and received
ampicillin, then amoxicillin, and erythromycin and other
antibiotics (Table 1) for one week. CDI symptoms developed
six days after discontinuing antibiotics. A positive EIA assay
for C. diﬃcile Toxin A was detected in her stool the next
day. She remained hospitalized and delivered at 29 weeks
gestation.
Patients received antibiotics for both prophylaxis and to
treat infections. The indication for antibiotic use and actual
antibiotic exposures are presented in Table 1. Ten of the 20
cases received a combination of ampicillin, gentamicin, and
clindamycinforchorioamnionitisorpostpartumendometri-
tis. Two additional cases received clindamycin: one alone for
GBS prophylaxis and one together with other antimicrobials
for mastitis. Thus, 12 of the 20 cases received a regimen that
included clindamycin. Two cases received a cephalosporin
alone for Cesarean prophylaxis. One patient diagnosed with
CDI in September received no antibiotics.
Antibiotics were used to treat chorioamnionitis and/or
postpartumendometritisin12ofthe20patients.Threecases
received antibiotics for infections unrelated to pregnancy;
they were among the 5 patients with long-term antepartum
hospitalizations for signiﬁcant chronic illnesses including
Marfan’s syndrome, class RF diabetes, chronic hypertension,
osteosarcoma, and sickle cell anemia with crisis. All of these
5 also had signiﬁcant obstetrical complications, including
premature delivery.
A total of 8 patients required hospital readmission after
delivery for diarrhea and fever. The readmission to the
postpartum unit could have contributed to the outbreak
from C. diﬃcile contamination of this hospital area. Two
discharged postpartum patients were treated with outpatient
therapy. Extra days of hospitalization for those inpatients
diagnosed with CDI cannot be precisely calculated, but the
eight patients readmitted for CDI required a total of 22 extra
inpatient days or an average of almost 3 extra days per case.
The morbidity among the cases was signiﬁcant. All 20
patients presented with diarrhea. Fever during CDI was
documentedin16cases,aleukocytosisofgreaterthan15,000
in 9 cases and a creatinine of greater than 1.0 in 4 cases. One
patient developed septic shock and toxic mega colon, but no
deaths occurred in this series.
A 52-year-old postpartum case suﬀered a toxic mega-
colon and required an emergent colectomy despite prompt
oral metronidazole treatment for one day and subsequent
oralandrectalvancomycin.Thepatienthadatwingestation;
one twin delivered vaginally and the second twin by emer-
gent cesarean section. She received cefazolin prophylaxis
with surgery. On postoperative day 2, she developed a
38.9◦ temperature and received ampicillin, gentamicin, and
clindamycin for postpartum endometritis. Antibiotics were
discontinuedonthe4thpostoperativeday,butshedeveloped
diarrhea later that day. A positive EIA assay for C. diﬃcile
Toxin A and a positive cytotoxin assay for Toxin B were
identiﬁed in her stool on postoperative day 5, and she was
promptly placed on metronidazole. The next morning, she
developed septic shock: oliguria, tachycardia, hypotension, aInfectious Diseases in Obstetrics and Gynecology 5
Table 2: Selected characteristics of CDI cases and of randomly selected controls.
Cases (N = 20) Controls (N = 80) OR (95% CI) P-value
Mean age ± S.D. 30.6 ± 9.3 29.0 ± 7.2 0.2
Ethnicity
Caucasian 12 (60%) 41 (51%)
African American 3 (15%) 8 (10%)
Hispanic 3 (15%) 14 (18%) 0.9
Asian/Paciﬁc Islander 1 (5%) 8 (10%)
Other/unknown 1 (5%) 8 (10%)
Mode of delivery 14 (70%) 27 (34%) 4.6 (1.6–13.3) 0.03
Cesarean section
Signiﬁcant underlying illness 5 (25%) 6 (8%) 4.1 (1.2–15.2) 0.04
Prior antepartum
hospitalizations 11 (55%) 2 (3%) 47.7 (9.1–250.0) 0.001
Complications
Preterm labor 2 (10%) 8 (10%) 1.0 (.20–5.1) 1.0
PPROM 3 (15%) 4 (5%) 3.4 (.06–1.5) 0.1
Chorioamnionitis 7 (35%) 4 (5%) 10.2 (2.9–39.9) .001
Postpartum endometritis 5 (25%) 2 (3%) 13.0 (2.3–73.4) .003
Any antibiotic use 19 (95%) 45 (56%) 14.8 (1.9–115.8) 0.001
Antibiotic combinations
Amp/Gent/Clinda 10 (50%) 2 (3%) 39.0 (7.5–204.0) <.001
Clindamycin alone 2 (10%) 2 (3%) 4.3 (.57–32.9) 0.2
Cefazolin/Keﬂex 10 (50%) 24 (30%) 2.3 (0.9–6.3) 0.9
Other 6 (30%) 2 (3%) 16.7 (3.1–91.3) .001
>3 doses of IV antibiotics 18 (90%) 14 (18%) 42.4 (8.8–204.0) <.001
∗Categorical variables testing using chi-square or Fischer’s exact test; continuous variables tested using the Mann Whitney U test.
leucocytosis (12.9THOU/μL), and a creatinine of 2.4mg/dL.
Vancomycin was begun both by a nasogastric tube and
rectally, and she was transferred to the intensive care unit.
The patient’s clinical condition worsened on postoperative
day 7, and a total colectomy was performed. Histopathologic
examination of the resected colon conﬁrmed the diagnosis
of toxin megacolon and pseudomembranous colitis. This
patienthadnosigniﬁcantbaselineriskfactorsforCDIexcept
for her age.
All infection control measures were implemented by
the end of January 2007 (Figure 1). Changes to antibiotic
prescribing protocols were in place by spring of 2007. One
additional cases of peripartum CDI was diagnosed in the
36 months since outbreak ended June 2007. This patient
was not included in the report because she transferred with
CDI from an outside hospital. She presented with sepsis,
pseudomembranous colitis, and a positive Toxin B assay.
3.1. Case-Control Study. Univariate analyses results compar-
ing the 20 CDI cases with 80 randomly chosen unmatched
controls are presented in Table 2. The two groups did not
diﬀer in age or ethnicity. Women with CDI were more likely
than controls to have undergone a cesarean section (70%
versus 34%; P = 0.03), been previously hospitalized during
the pregnancy (55% versus 2.5%; P = 0.001), and have
signiﬁcant underlying illness (25% versus 7.5%; P = 0.04).
Underlying illness in the case group included Marfan’s
syndrome,classRFdiabetes,chronichypertension,sicklecell
anemia with sickle crisis, osteosarcoma, and a signiﬁcant
neck venous malformation.
CDI cases undergoing cesarean section often had a long
labor and a diagnosis of chorioamnionitis or postpartum
endometritis. CDI was associated with both chorioam-
nionitis (OR 10.2, 95% CI 2.9–39.9) and postpartum
endometritis (OR 13.0, 95% CI 2.3–73.4). The use of any
antibiotic was strongly associated with CDI (OR 14.8, 95%
CI 1.9–115.8) as was the use of the combination ampi-
cillin/gentamicin/clindamycin (OR 39.0, 95% CI 7.5–204.0).
The combination of ampicillin/gentamicin/clindamycin was
used for 10 cases and only 1 control (P<. 001). Three or
more intravenous antibiotic doses (range 3 to 40 doses) were
received by 18 cases and only 14 controls (P<. 001).
Three risk factors in the univariate analyses were
both strongly associated with CDI and with each other:
cesarean section delivery, any antibiotic use, and use of
ampicillin/gentamicin/clindamycin. Thus, these three risk6 Infectious Diseases in Obstetrics and Gynecology
Table 3: Infection control measures used for an obstetrical service
outbreak of Clostridium diﬃcile Infection (CDI).
(1) Contact precautions
(a) Intensive education and training in the fundamentals of
infection control.
(b) Contact precautions for all suspected and documented CDI
cases.
(2) Hygiene
(a) Thorough hand hygiene with soap and water rather than an
alcohol-based hand gel when caring for patients with suspected or
documented CDI.
(b) Water-based surgical scrub for the ﬁrst case of the day, and
when hands are visibly soiled.
(3) Positive protective equipment (PPE) for potential exposure
(a) Gowns and gloves for contact with any suspected and
documented CDI cases.
(b) Frequent change of scrubs and protective garments.
(4) Environmental and equipment cleaning
(a) Extensive environmental cleaning and disinfection of the entire
unit and outpatient clinic with a hypochlorite-based disinfectant.
(b) Replace carpet in provider work rooms with laminated hard
wood ﬂoors
(5) Diagnosis and treatment
(a) Prompt diagnosis of patients with diarrhea.
(b) Prompt treatment of documented CDI or suspected CDI in
seriously ill patients.
(c) Good antibiotic stewardship with minimal clindamycin and
multiple antibiotic regimen use.
factors were examined in a logistic regression. In a binary
logistic regression model, the use of the combination ampi-
cillin/gentamicin/clindamycin persisted as an independent
risk factor for CDI (P<0.001). This conﬁrmed the strong
association present in the univariate analysis.
4. Discussion
This peripartum CDI outbreak is the largest sustained
outbreak reported to date on a labor and delivery unit
[6, 8–10, 21]. A PubMed search of English citations from
1966 to April 2011 conﬁrms previous reports of only up
to 4 peripartum CDI cases in one institution [9]. Prior
reports estimated the rates of peripartum CDI to range
widely from 0.4 to 0.7 per 100,000 deliveries where the
diagnosis was made from national coding data [6]t o0 . 7
per 1000 admissions where the diagnosis was extracted from
microbiology laboratory log data [21] .T h ec a s er a t eo f7 . 5
CDI infections per 1000 deliveries over the 15 months of this
outbreak was comparable to the rate of 10–20 CDI infections
per 1000 hospital discharges during recent CDI outbreaks in
nonpregnantadults[4,5].Incontrasttotheseoutbreaks,our
patients were young women without typical risk factors such
as prolonged hospitalization, prior ICU stay, or, for many,
signiﬁcant underlying illness.
Two well-recognized CDI risk factors were present in
almost all but one case: prior antimicrobial use and hospital
exposure. Antibiotic use is particularly high in modern
delivery services; 56% of the UWMC control patients in
this study received at least one antibiotic dose. Multiple
antibiotics were used simultaneously and/or sequentially in
85% of the CDI cases, and 3 or more antibiotic doses were
given to 90% of cases.
Examinationofantibioticsusedpriortothedevelopment
of CDI suggests that the regimen of ampicillin, gentamicin,
and clindamycin was a major factor in the outbreak.
Repeated doses of this antibiotic regimen were strongly
associated to CDI in both the univariate and in the multi-
variateanalyses,independentofthemodeofdeliveryandany
antibiotic use. This potent combination of antimicrobials
is popular in labor and delivery units because of its wide
microbial coverage [17, 18], and it was used at UWMC for
both chorioamnionitis and postpartum endometritis for the
past 20 years. Both the multiple antibiotic combinations and
its long time of use at UWMC may have acted synergistically
to contribute to the outbreak.
Cd i ﬃcile recovered from cases was not tested for clin-
damycin resistance in our report, but antibiotic resistance
contributed to hypervirulent CDI strains in other outbreaks
[22]. Previous reports found that up to 80% of C. diﬃcile
isolates were resistant to clindamycin, [23] and 60% of our
cases received clindamycin. Since the outbreak, TimentinR
has been used to treat chorioamnionitis and endometritis.
The lack of TimentinR (ticarcillin/clavulanate) resistance to
C. diﬃcile at UWMC and an expected comparable infection
treatment result [17] made the switch logical. TimentinR
caries a <1% resistance to C. diﬃcile, although extended
penicillins, like all antibiotics, have been implicated in
CDI.
A meta-analysis on the CDI risk from various antimicro-
bials listed, in order of higher to a lower magnitude includes:
second and third generation cephalosporins, amoxicillin or
ampicillinwithclavulanicacid,antipseudomonal penicillins,
clindamycin, quinolones, aminoglycosides, ampicillin, and
penicillin [24]. However, in the recent serious hypervirulent
NAP1/027 CDI Quebec outbreak, quinolones were partic-
ularly singled out with a population attributable fraction
of 36% [25]. The NAP1 C. diﬃcile strain is not only
ﬂuoroquinolone resistant, but the hypervirulence is derived
f r o mi t sa b i l i tyt op r o d u c e1 6t o2 3t i m e sm o r et o x i nAa n dB
in vitro than toxin type O strains [26, 27]. Fluoroquinolones
are relatively contraindicated in pregnancy, so they were
not a factor in this peripartum CDI outbreak. The 56%
antibiotic use rate in a delivery unit such as at UWMC is
both astounding and common. Obstetrical units should pay
close attention to antibiotic use and be prepared to institute
antibiotic rotation, such as occurred here.
Strong environmental control measures and an infection
control “bundle” together with antimicrobial stewardship
are recommended to control a CDI outbreak [5, 21, 28,
29]. It is impossible to assess the relative impact of the
environmental interventions compared to antibiotic change
in the cessation of this outbreak. Stepwise environmental
and behavioral infection control measures and antibiotic
changes were put in place simultaneously until the outbreak
ended. However, despite a marked reduction in CDI afterInfectious Diseases in Obstetrics and Gynecology 7
these measures were in place in December 2006, sporadic
CDI cases continued for 6 months. The infection control
methods used for the UWMC outbreak included: education,
hand washing with soap and water, attention to clean
scrub clothes, gown and glove use, environmental chlorine-
based cleaning of patient rooms and bathrooms, and all
nursing and physician work areas, together with a change
of antimicrobials. It should be noted that spores are more
poorlyinhibitedbytheneweralcohol-basedwater-freehand-
washing solution than with soap and water,and thereforethe
mechanical removing of potential C. diﬃcile spores by hand
washing is recommended [12]. Still, the contribution to this
outbreak of water-free-hand washing solution is unknown.
Environmental cleaning with chlorine-based cleaning agents
iseﬀectivetoreduceCDIoutbreaks[6,12].Thoughwecould
not determine which speciﬁc infection control measures
ended the outbreak, only one case was reported since June
2007,andthispatientwastransferredwithCDIfromanother
hospital.
CDI is treated by discontinuation of the implicated
antimicrobial and the administration of oral metronidazole
for mild-moderate disease or vancomycin for moderately
severe or persistent disease [12]. Oral metronidazole initially
was used to treat all young UWMC peripartum women; it is
inexpensive and therapeutically equivalent to vancomycin in
clinicaltrialsofmoderatedisease[28].However,vancomycin
is recommended for severe diseases, because it is not
absorbed from the gut, it stops toxin production, its colon
lumen concentration is 50 to 200 times higher than the
MIC of C. diﬃcile, and vancomycin resistant C. diﬃcile
has not been reported [30]. The severe CDI case resulting
in a colectomy in this outbreak was treated for one day
with metronidazole, as she appeared to have mild-moderate
disease. She rapidly developed septic shock so that even
immediate vancomycin therapy may not have inﬂuenced
this malignant course of CDI. Other peripartum patients
in published reports also required colectomy [9, 10]. Thus,
obstetricprovidersneedtobeawarethatperipartumpatients
with CDI are at risk for severe and rapidly progressing
disease, possibly because of depressed immunity during
pregnancy [9]. Moreover, women with underlying disease
may be at increased risk of peripartum CDI.
Hospital obstetrical units pose a unique opportunity for
infection control. The environment is purposely designed
to create intimacy and a “natural” environment for labor
and delivery. However, as we found, this environment also
provides ample reservoirs and transmission modes for C.
diﬃcile infections. Providers have frequent contact with fecal
contents during a delivery and travel from one patient room
to another in the labor and delivery unit. In these high
volume units, rooms are quickly cleaned for reuse, and
infectious disease recognition can be neglected. In this unit,
readmission of postpartum patients to the postpartum ward
also may have contributed to the outbreak. Great vigilance
must be taken on multiple levels to decrease the exposure of
patientstoantibioticharmandtovigorouslyworktoidentify
and prevent outbreaks of CDI.
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